The arylamine N-acetyltransferase (NAT2) polymorphism and the risk of adverse reactions to co-trimoxazole in children

European Journal of Clinical Pharmacology

Volumn 54, Issue 9-10, 1998, Pages 779-785

  Zielinska E ^a   Niewiarowski, W ^b   Bodalski, J ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b CENTRE OF MOLECULAR AND MACROMOLECULAR STUDIES   (Poland)

Author keywords

Adverse reactions; Co trimoxazole

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; COTRIMOXAZOLE;

ARTICLE; CHILD; CLINICAL ARTICLE; DRUG ACETYLATION; FEMALE; GENE MUTATION; GENETIC DISORDER; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INFANT; INTERSTITIAL PNEUMONIA; KIDNEY DISEASE; LIVER DISEASE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION MAPPING; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME;

ACETYLATION; ALLELES; ANTI-INFECTIVE AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; CHILD, PRESCHOOL; FEMALE; GENOTYPE; HUMANS; INFANT; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0345628578     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050551     Document Type: Article

References (44)

1. Davey RTJ, Masur H (1990) Recent advances in the diagnosis, treatment and prevention of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 34: 499-504
2. Goodwin SD (1993) Pneumocystis carinii pneumonia in human immunodeficiency virus-infected infants and children. Pharmacotherapy 13: 640-646
3. Grossi P, Ippoliti GB, Goggi C, Cremaschi P, Scaglia M, Minoli L (1993) Pneumocystis carinii pneumonia in heart transplant recipients. Infection 21: 75-79
4. Kramer MR, Stoehr C, Lewiston NJ, Starnes VA, Theodore J (1992) Trimethoprim-sulfamethoxazole prophylaxis for Pneumocystis infections in heart-lung and lung transplantation - how effective and for how long? Transplantation 53: 586-589
5. Boyce TG, Smidt RG, Edmonson MB (1992) Fever as an adverse reaction to oral trimethoprim-sulfamethoxazole therapy. Pediatr Infect Dis J 11: 772-773
6. Carbon C, Richard A, Bons B (1994) Pseudomembranous colitis caused by antibiotic therapy. Results of a survey of the patient material from the praxis of 900 gastroenterologists. Therapie 49: 325-331
7. Gupta A, Eggo MC, Uetrecht JP, Cribb AE, Daneman D, Rieder MJ, Shear NH, Cannon M, Spielberg SP (1992) Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther 51: 56-57
8. Hughes WT, LaFon SW, Scott JD, Masur H (1995) Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia. J Infect Dis 171: 1295-1301
9. Lim JT, Chan HL (1992) Fixed drug eruptions due to cotrimoxazole. Ann Acad Med Singapore 21: 408-410
10. Murphy JL (1992) Renal tubular acidosis in children treated with trimethoprim-sulfamethoxazole during therapy for acute lymphoid leukemia. Pediatrics 89: 1072-1074
11. Pederson-Bjergaard U, Anderson M, Hansen PB (1997) Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy. Eur J Clin Pharmacol 52: 183-189
12. Cribb AE, Spielberg SP (1992) Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin Pharmacol Ther 51: 522-526
13. Curtis BR, McFarland JG, Wu GG, Visentin GP, Aster RH (1994) Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopies on the glycoprotein IIb/IIIa complex. Blood 84: 176-183
14. Lee BL, Delahunty T, Safrin S (1994) The hydroxylamine of sulfamethoxazole and adverse reactions in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 56: 184-189
15. Meekins CV, Sullivan TJ, Gruchalla RS (1994) Immunochemical analysis of sulfonamide drug allergy: identification of sulfamethoxazole-substituted human serum proteins. J Allergy Clin Immunol 6: 1017-1024
16. Ven AJAM van der, Vree TB, Koopmans PP, Nijmegen van der M (1997) Metabolites and side effects of trimethoprim-sulfonamide combinations. Chemotherapie J 6: 28-30
17. Cribb AE, Nakamura H, Grant DM, Miller MA, Spielberg SP (1993) Role of polymorphic and monomorphic human arylamine N-acetyltransferase in determining sulfamethoxazole metabolism. Biochem Pharmacol 45: 1277-1282
18. l-glucuronide conjugates in healthy human volunteers. Clin Drug Invest 9: 43-53
19. Vree TB, van der Ven AJAM, (1997) Clinical pharmacokinetics of sulphonamides. Chemotherapie J 6: 21-27
20. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP (1991) Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 49: 13-17
21. Carr A, Gross AS, Hoskins JM, Penny R, Cooper DA (1994) Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients. AIDS 8: 333-337
22. Deguchi T (1992) Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. J Biol Chem 267: 18140-18147
23. Agúndez JAG, Martinez C, Olivera M, Ledesma MC, Ladero JM, Bentez J (1994) Molecular analysis of the arylamine N-acetyltransferase polymorphism in a Spanish population. Clin Pharmacol Ther 56: 202-209
24. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I (1995) Arylamine N-acetyltransferase (NAT2) mutations and their linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 57: 581-592
25. Mrozikiewicz PM, Cascorbi I, Brockmoller J, Roots I (1996) Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. Clin Pharmacol Ther 59: 376-382
26. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, Kadlubar FF, Lucier GW (1993) Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 14: 1689-1692
27. 341 803) and wild-type human polymorphic N-acetyltransferase (NAT2) alleles. Drug Metab Dispos 22: 371-376
28. Bigler J, Chen CH, Potter JD (1997) Determination of human NAT2 acetylator genotype by oligonucleotide ligation assay. BioTechniques 22: 682-690
29. Delomenie C, Grant DM, Mathelier-Fusade P, Jacomet C, Leynadier F, Jacqz-Aigrain E, Rozenbaum W, Krishanmoorthy R, Dupert JM (1994) N-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients (letter). Br J Clin Pharmacol 38: 581-582
30. Wolkenstein P, Carriere V, Charue D, Bastuji-Garin S, Revuz J, Roujeau JC, Beaune P, Bagot M (1995) A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics. 5: 255-258
31. Zielińska E, Niewiarowski W, Bodalski J, Rȩbowski G, Piotrowska J, Skrȩtkowicz J, Mianowska K, Sekulska M (1997) N-acetyltransferase genotyping in children is more sensitive in predicting adverse reactions to trimethoprim-sulfametoxazole than acetylation phenotyping. In: Luscombe DK, Husson MC, Caramona M (eds) Progress in clinical pharmacy. Optimising the pharmacotherapy process. Proceedings of the 25th European symposium on clinical pharmacy, Lisbon 1996. European Society of Clinical Pharmacy, pp 176-181
32. Rolfs A, Schuller I, Fincken U, Weber-Rolfs 1 (1992) PCR. Clinical diagnostics and research. Springer-Verlag Berlin Heidelberg New York, pp 79-89
33. Hickman D, Sim E (1991) N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem Pharmacol 42: 1007-1014
34. Zielińska E, Niewiarowski W, Bodalski J, Rȩbowski G, Matusiak I (1997) Molecular genotyping of the arylamine N-acetyltransferase polymorphism in children. Med Sci Monit 3: 661-668
35. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DAP, Grant DM, Hein DW, Hickman D, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T, Yamazoe Y (1995) Nomenclature for N-acetyltransferases. Pharmacogenetics 5: 1-17
36. Blum M, Demierre A, Grant DM, Heim M, Meyer UA (1991) Molecular mechanism of slow acetylation of drugs and carcinogens in human. Proc Natl Acad Sci USA 88: 5237-5241
37. Grant DM (1993) Molecular genetics of the N-acetyltransferase. Pharmacogenetics 3: 45-50
38. Meisel M, Schneider T, Siegmund W, Nikschick S, Klebingat KJ, Scherber A (1986) Development of human polymorphic N-acetyltransferase. Biol Res Pregnancy 7: 74-76
39. Peng D, Birgersson C, von Bahr C (1984) Polymorphic acetylation of 7-aminoclonazepam in human liver cytosol. Pediatr Pharmacol 4: 155-158
40. Szorady I, Santa A, Veress I (1987) Drug acetylator phenotypes in newborn infants. Biol Res Pregnancy Perinatol 8: 23-25
41. Pariente-Khayat A, Pons G, Richard MO, D'athis P, Moran C, Badoual J, Olive G (1991) Caffeine acetylator phenotyping during maturation in infants. Pediatr Res 29: 492-495
42. Lorenzo B, Reidenberg MM (1989) Potential artifacts in the use of caffeine to determine acetylation phenotype. Br J Clin Pharmacol 28: 207-208
43. Zielińska E, Bodalski J, Niewiarowski W, Bolanowski W, Matusiak I (1998) Comparison of acetylation phenotype with genotype coding for N-acetyltransferase (NAT2) in children. Pediatr Res (in press)
44. Blaser J, Joos B, Opravil M, Lüthy R (1993) Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy. Infection 21: 206-209